Infliximab-Dyyb
1 NDC across 1 manufacturer|0 Generic,1 Brand
Infliximab-Dyyb is used to treat psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, crohn disease and ankylosing spondylitis, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
In 2024, Medicare Part D spent $40 million on Infliximab-Dyyb across 7,306 claims for 1,482 beneficiaries.
Infliximab-Dyyb is available as 1 NDC from 1 manufacturer (0 generic, 1 brand), with NADAC prices from $491.55 to $491.55 per EA. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
1
0G / 1B
Manufacturers
1
competing in market
Price Spread
$491.55 – $491.55
per EA
7d Activity
avg +0.0% WoW · of 1 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Pfizer Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Tumor Necrosis Factor Blocker class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing INFLIXIMAB-DYYB
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
INFLECTRA 100 MG VIAL | $491.5457 per EA | — |
Frequently Asked Questions
What is Infliximab-Dyyb used to treat?
Infliximab-Dyyb is used to treat psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, crohn disease and ankylosing spondylitis, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Infliximab-Dyyb?
In 2024, Medicare Part D spent $40 million on Infliximab-Dyyb across 7,306 claims for 1,482 beneficiaries.
How many Infliximab-Dyyb products are on the market?
The Infliximab-Dyyb drug market contains 1 NDC from 1 manufacturer — 0 generic and 1 brand product.
What is the price range for Infliximab-Dyyb?
NADAC reference prices for Infliximab-Dyyb range from $491.5457 to $491.5457 per EA.
Which manufacturers make Infliximab-Dyyb?
1 manufacturer lists Infliximab-Dyyb in NADAC. Ranked by number of NDCs, the largest are Pfizer Inc. (1).